NCT07200492

Brief Summary

This clinical study is a single-center, randomized, split-face, on-site controlled trial conducted at Shanghai China-Norm Quality Technical Service Co., Ltd. The primary objective is to evaluate the efficacy of Eucerin Ultrasensitive Repair Intensive Source Serum in providing instant and long-lasting (24-hour) soothing and repairing effects under induced redness conditions. The design involves recruiting 30 healthy Chinese female subjects aged 18-60 years, who meet stringent inclusion/exclusion criteria, including absence of skin conditions and no recent participation in similar studies. Redness is induced using 50% Glycolic Acid on the entire face and tape stripping on both forearms.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 15, 2024

Completed
7 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 22, 2024

Completed
2 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 24, 2024

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

September 11, 2025

Completed
20 days until next milestone

First Posted

Study publicly available on registry

October 1, 2025

Completed
Last Updated

October 1, 2025

Status Verified

September 1, 2025

Enrollment Period

7 days

First QC Date

September 11, 2025

Last Update Submit

September 22, 2025

Conditions

Outcome Measures

Primary Outcomes (6)

  • Skin Erythema Index via Mexameter® MX 18

    From Baseline to 24-hour after product repeat application

  • Colorimetry (avalue) via Chromameter CM26dG *

    from Baseline to 24-hour after product repeat application

  • Skin Scaliness (Desquamation) via Squamescan® 850A

    from Baseline to 24-hour after product repeat application

  • Forearm Skin Redness (avalue) via Cross-Polarized Light Imaging *

    The a\*value is a parameter in the CIELAB color space (also known as Lab) that quantifies a color's position along the red-green axis .

    From Baseline to 24-hour after product repeat application

  • Facial Skin Redness and Colorimetry (a* value) via VISIA-CRP Imaging

    from Baseline to 24-hour after product repeat application

  • Skin Surface Evenness (SEsc) via UV Video Capture and SELS Analysis

    from Baseline to 24-hour after product repeat application

Study Arms (4)

Facial Test Arm

OTHER
Other: Facial serum application

Facial Control Arm

NO INTERVENTION

Arm Test Arm

OTHER
Other: Forearm serum application

Arm Control Arm

NO INTERVENTION

Interventions

The trained technician will apply the 0.3g-0.4g investigational products on the subject's half face.

Facial Test Arm

The trained technician will apply the (2mg±0.1mg)/cm² investigational products on the subject's forearm.

Arm Test Arm

Eligibility Criteria

Age18 Years - 60 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Chinese female whose age range from 18 to 60 years old;
  • Be in general good health and good mental state;
  • Have no any broken,scars,birthmarks and other imperfections on the test area;
  • Redness/erythema≥grade 2 after modelling inducing and the score of redness must be increased after inducing;
  • Not currently be participating in any other study involving the test area(Face and Forearm);
  • Not have participated in any other study involving the test area in the past one month;
  • Be willing to read,understand and able to sign the Informed Consent Form and Photo Release From;
  • Be willing to comply with all study protocol requirements.

You may not qualify if:

  • Intending to get pregnant, be pregnant, be lactating, be within 6 months of delivery or be unwilling to take necessary precautions to avoid a pregnancy;
  • Having used antihistamine drugs in the past 1 week or immunosuppressants in the past 1 month;
  • Taken anti-allergic drug/injections in the past 1 month;
  • Presently have allergies, allergic dermatitis or skin disease;
  • Have sensitivity or even allergy to topical products, ingredients or fragranced products;
  • Have history of allergies;
  • Have history of suffering from skin diseases (such as psoriasis, eczema, skin cancer, etc.);
  • Have used any anti-inflammatory treatment on the test area within 2 months prior to this study starting date;
  • Has a chronic medical condition that may interfere with testing (e.g., asthma, insulin-dependent diabetes, lupus, rheumatoid arthritis or other immune/auto-immune diseases);
  • Have used any scrubs or peeling product (regardless of method) or self-tanning products or oil control products in the past 3 days;
  • Have received cosmetic medical procedures on the face (such as injectable anti-wrinkle products, cosmetic surgery, tattoo removal, home light facial procedures or home use medical devices, etc.) in the past 1 month;
  • Have excessive sun exposure or ultraviolet light exposure in the past 1 month;
  • Have applied ortho-hydroxybenzoic acid, hydroquinone in the past 3 months; or used prescriptions (such as antibiotic, retinoids, alpha hydroxyl acid and steroid), oral contraceptives;
  • Avoid providing emergency contact;
  • Subjects that are not compliant with the selection criteria or not proper for participation as determined by Principal Investigator;
  • +1 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shanghai China-norm Quality Technical Service Co., Ltd.

Shanghai, Shanghai Municipality, 200072, China

Location

MeSH Terms

Conditions

Erythema

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue DiseasesSkin ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2025

First Posted

October 1, 2025

Study Start

January 15, 2024

Primary Completion

January 22, 2024

Study Completion

January 24, 2024

Last Updated

October 1, 2025

Record last verified: 2025-09

Locations